Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23834830 | 1.00 | MAPT (0.39) | MAPTKMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL25312299 | 0.87 | MAPT (0.34) | MAPTKMT2AGAA | |
| SCHEMBL189364 | 0.85 | RAPGEF4 (0.33) | MAPTKMT2AALDH1A1 | |
| SCHEMBL2925416 | 0.81 | CYP3A4 (0.35) | — | |
| SCHEMBL29921242 | 0.79 | MAPT (0.38) | MAPTKMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL13236485 | 0.79 | RIPK1 (0.35) | MAPTKMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL23835482 | 0.79 | MAPT (0.38) | MAPTKMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL22320062 | 0.77 | MAPT (0.30) | MAPTKMT2A | |
| SCHEMBL29393235 | 0.77 | MAPT (0.30) | MAPTKMT2A | |
| SCHEMBL27129828 | 0.77 | RAPGEF4 (0.31) | MAPTKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-119241481-A | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-115298170-B | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | disclosed |
| CN-115298170-A | Biaryl derivatives as inhibitors of YAP/TAZ-TEAD protein-protein interactions | 诺华股份有限公司 | 2022-11-04 | — | — | CN | disclosed |